Tag Archives: Earnings

Friday, March 29th 2019 at 12:30pm UTC –Initiated ZEPHYR, a pivotal Phase 2b/3 clinical study of livoletide for patients with Prader-Willi syndrome (PWS), in 1Q19– –Topline data from Phase 2b Portion of ZEPHYR and Phase 2b clinical study of nevanimibe for classic congenital adrenal hyperplasia (CAH) expected in 1H20– –Completed …

Friday, March 29th 2019 at 12:30pm UTC PARSIPPANY, N.J.–(BUSINESS WIRE)– Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 2, 2019. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Glenn David will review first quarter 2019 …

Thursday, March 28th 2019 at 8:15pm UTC Total Revenue in Q4 was $22.9 Million SaaS revenue of $17.3 million in Q4, up 9% from Q3 Enhanced efficiencies continued to drive significantly lower operating expenses in both Q4 and full year of 2018 For 2018, substantially improved adjusted Non-GAAP bottom line …

Thursday, March 28th 2019 at 8:05pm UTC Conference call begins today at 4:30 p.m. Eastern time EMERYVILLE, Calif.–(BUSINESS WIRE)– NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, reports financial results for the three and 12 months ended December …

Thursday, March 28th 2019 at 12:00pm UTC IRVINE, Calif.–(BUSINESS WIRE)– Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced financial results for the quarter and year ended December 31, 2018 and provided updates …

Thursday, March 28th 2019 at 11:00am UTC Global distribution deals signed in Europe and China, including Can-Fite’s largest deal to date for up to $74.5 M Top-line data from Phase II Namodenoson trial in the treatment of liver cancer supports continuation into Phase III study Top-line Data from Phase II …

Wednesday, March 27th 2019 at 8:05pm UTC —Company delivers regulatory, scientific and commercial progress in four crops, and launches new strategy in cannabis— DAVIS, Calif.–(BUSINESS WIRE)– Arcadia Biosciences, Inc. (Nasdaq: RKDA), a food ingredient company and proven leader in agricultural innovation, improving the quality and nutritional content of crops, today …

Wednesday, March 27th 2019 at 10:35am UTC – 2018 marked by strengthening of executive team, expansion of commercial organization, bolstering of clinical and health economic data, and achievement of important regulatory milestones – – REDUCE study per protocol planned interim analysis showed statistical significance in the first 45 patients on …

Wednesday, March 27th 2019 at 6:30am UTC SENS-111 phase 2 AUV trial: major progress with 75% of patients enrolled in the clinical trial assessing the efficacy of SENS-111 on vertigo intensity SENS-111 phase 2a trial: the phase 2a trial has achieved its tolerance primary end point; SENS-111 affects neither the …

Monday, March 25th 2019 at 1:01pm UTC Entered into a merger agreement with C3J Therapeutics that is expected to result in an NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics $10.0 million of new capital will be invested in combined company to be re-named Armata Pharmaceuticals Preliminary Merger …